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Summary
Aims. Inflammatory breast cancer (IBC) is an aggressive subtype of breast cancer with poor prognosis. The
mechanisms responsible for the aggressive clinical evolution are incompletely understood. We constructed a tissue
microarray (TMA) and validated its use in translational IBC research. Differential expression of proteins that might
play a role in causing the IBC phenotype was studied.
Methods and results. A TMA containing 34 IBC and 41 non-stage matched non-IBC tumours was constructed.
Five core biopsies were taken for each IBC and three cores for each non-IBC tumour. The TMA was validated using
three approaches: (1) the excellent concordance between immunohistochemical results of the initial pathological
examination and the results obtained with the TMA for ER, PR and HER2/neu (κ > 0.74); (2) the known differential
expression between IBC and non-IBC for four bio-markers in IBC (ER, PR, p53 and HER2/neu) was confirmed
( p < 0.01); (3) the HER2/neu status using three different antibodies (CB11, TAB250 and HercepTest) was highly
concordant (κ > 0.75). Furthermore, the overexpression of E-Cadherin and RhoC GTPase in IBC ( p < 0.05) was
confirmed. We did not find a differential expression pattern for carbonic anhydrase IX (CA IX) and EGFR.
Conclusions. Using different approaches, we have validated the use of our TMA for studying differential protein
expression in IBC and non-IBC. We confirm the overexpression of E-Cadherin and RhoC GTPase in IBC. The lack
of differential expression for CA IX and EGFR might suggest the pathways are equally utilised in both types of
breast cancer.
Introduction
Inflammatory breast cancer (IBC) is a well-defined
clinical and pathological subtype of breast cancer,
comprising up to 5% of all breast malignancies [1]. Al-
though major improvement in the treatment was made
with the introduction of a multi-modality approach,
the overall prognosis remains poor [2, 3]. The biolog-
ical behaviour of IBC is one of more local aggressive
growth, rapid haematogenous and lymphatic invasion
and as such is very different from other high-grade
invasive breast carcinomas, explaining the number of
involved lymph nodes and even distant metastases at
the time of diagnosis [1, 4]. Although validated bio-
markers of worse prognosis in breast cancer, such as
increased proliferation fraction, the HER2/neu ampli-
fication and the absence of steroid hormone receptors
are found in IBC [3, 5–11], these clearly fail to
explain the typical clinical course of patients suffer-
ing from IBC. Little is known about the underlying
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mechanisms of the rapid progression, strong an-
giogenesis and (lymph)angioinvasiveness and the
question remains whether and to what extent tumoural
and/or stromal factors are responsible for the specific
IBC phenotype. Better understanding of the IBC phe-
notype can not only lead to new prognostic markers
but might also suggest specific therapeutic targets for
IBC. Considering IBC as a unique human model of
early metastasis, these studies might also provide bet-
ter insight in tumour metastasis and tumour–stroma
interactions.
Most studies investigating specific molecules for
their eventual contribution to the IBC phenotype, star-
ted from tumour cell lines and animal model obser-
vations [12–14]. The authors confirmed their findings
on human material using immunohistochemical (IHC)
analyses of whole tissue sections with antibodies dir-
ected against molecules thought to be key players in
the IBC phenotype [15, 16]. Using whole tissue sec-
tion analysis too, others investigated the role in IBC of
molecules known to be pivotal in cancer progression
and metastasis [15, 17]. With these time-consuming
and labour-intensive techniques, the involvement of
RhoC GTPase and E-Cadherin in the IBC phenotype
has been demonstrated.
With the introduction of molecular biological tech-
niques such as gene microarray analysis and quant-
itative RT-PCR, the number of genes known to be
involved in tumourigenesis, cancer progression and
metastasis has dramatically increased. Using these
techniques, RNA expression data of thousands of
genes can be gathered in a limited number of tumours.
In the near future, we expect that these techniques
will reveal a large number of molecules involved in
the IBC phenotype. Differential RNA expression of
these candidate molecules has to be validated at the
protein level on large data sets. Therefore, in response
to the dramatic increase in new candidate bio-markers,
Sauter et al. developed the tissue microarray (TMA)
technique [18–20]. Using this technique, the protein
expression of hundreds of tumours can be evaluated
on one slide under standardised conditions. TMA tech-
nology has, to the best of our knowledge, never been
applied in IBC studies. Knowing the specific biology
and growth pattern of IBC, general concerns about us-
ing TMA technology such as sampling-bias and tissue
loss, have to be carefully considered and investigated.
The aim of this study is the implementation of the
TMA technique in the translational IBC research. We
have investigated methodological problems and val-
idated the use of our TMA for studying differential
protein expression in IBC. Furthermore, we studied
the differential protein expression of less investigated
molecules in IBC, which could be playing a role in this
unique breast cancer phenotype.
Materials and methods
Construction of TMA
Using the Beecher Instruments Tissue Arrayer
(Beecher Instruments, Silver Springs, MD, USA) an
IBC TMA was constructed. Thirty-four consecutive
IBC patients and 41 control non-stage matched breast
cancer patients were included in this study. All IBC
patients presented with a recently (≤8 weeks, me-
dian ≤5 weeks) developed diffuse enlargement of the
breast with redness and oedema of more than 1/3rd
of the skin of the breast. This IBC population was
previously described [17]. The average age of the IBC
patients was 56 years (range: 25–83 years).
The non-IBC control population consisted of 16
T1, nine T2, 10 T3 and six T4a breast cancer patients.
Average age of the control population was 58 years
(range 32–80 years). The TMA was planned to contain
five and three core biopsies for every IBC and non-
IBC tumour, respectively. Figure 1 shows the TMA
as it was planned at the beginning of this study. The
TMA can be divided into two parts. Columns 1 and 2
contain five core biopsies of 26 and eight IBC tumours
respectively. Column 3 contains three core biopsies of
16 T1 and nine T2 tumours, column 4 contains three
core biopsies of 10 T3 and six T4 tumours.
IHC staining
Five micrometer slides were cut from the TMA
and immunohistochemical (IHC) staining was per-
formed for the following antigens: estrogen receptor
(ER), progesterone receptor (PR), p53, E-Cadherin,
HER2/neu, Carbonic anhydrase IX (CA IX), epi-
dermal growth factor receptor (EGFR) and RhoC
GTPase (RhoC). IHC for the HER2/neu antigen was
done using three different antibodies (CB11, TAB250
and HercepTest). Table 1 shows the antigens IHC ana-
lysis was performed for on this TMA, mentioning the
primary antibody, the pre-treatment and the detection
system used.
Validation
To validate our TMA for studying differential protein
expression in IBC, three aspects were studied.
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Figure 1. TMA of IBC as planned at the beginning of this study. It consists of four columns and 26 rows. Column 1 (C1) and 2 (C2) contain
five core biopsies from 26 and eight IBC tumours, respectively. Column 3 (C3) and four (C4) contain 41 non-stage matched non-IBC tumours,
divided into four groups: Column 3A (C3A) contains 16 T1 breast tumours, Column 3B (C3B) contains nine T2 breast tumours, Column 4A
(C4A) contains 10 T3 breast tumours and Column 4B (C4B) contains six T4 breast tumours.
Concordance between results of the pathology
report and the TMA results
Whole tissue section IHC analysis for the ER, PR, p53
and HER2/neu antigen as described in the pathology
report were reviewed (PV and GVdE), if original IHC
slides were available. These results were compared to
the IHC results for these bio-markers using our TMA.
For interpretation of the IHC reactivity, the mean score
of all available core biopsies per patient was calcu-
lated. For ER and PR, the percentage of tumour cells
with nuclear immunoreactivity was scored on a 0–4
scale (0 = 0% positive tumour cells, 1 = 1–9% posi-
tive tumour cells, 2 = 10–49% positive tumour cells,
3 = 50–99% positive tumour cells, 4 = 100% positive
tumour cells). Furthermore, ER and PR status were
determined based on this score: Score 0–1 was con-
sidered ER or PR negative, score 2–4 was considered
ER or PR positive.
For the p53 antigen, a patient was considered p53
positive when more than 10% of tumour cells showed
nuclear immunoreactivity.
The HER2/neu score using the HercepTest
(DakoCytomation, Glostrup, Denmark) was inter-
preted on a 0–3 score (0 = no staining or membranous
staining in less than 10% of tumour cells; 1 = faint
or barely perceptible partial membranous staining in
more than 10% of tumour cells; 2 = weak to complete
membranous staining in more than 10% of tumour
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Table 1. Antigens IHC analysis was performed for on this TMA, mentioning the primary antibody (clone,
producer, dilution, incubation time), pre-treatment and detection system used
Antigen Primary antibody (clone, producer Pre-treatment Detection system
dilution, incubation time) (producer)
ER 6F11, Novocastra, Newcastle, UK WWBb StreptABCd
(1/25, 1 h) (98◦C);
PR 16, Novocastra, Newcastle, UK citrate buffer
(1/300, 1 h) (30 min)
p53 D0-7, Novocastra, Newcastle, UK LSABd
(1/300, 30 min)
E-Cadherin HECD-1, Takara, Kyoto, Japan StreptABCd
(1/80, 1 h)
HER2/neu CB11, Novocastra, Newcastle, UK None
HER2/neu TAB250, Zymed, San Francisco, CA, USA
(1/50, 1 h)
CA IX Antibody kindly provided by Prof EnVisiond
Dr A. Harris (1/50, 1 h)
HER2/neu HercepTestd
EGFRa EGFR PharmDx kitd
RhoC GTPase Antibody kindly provided by WWBb (98◦C); EnVisiond
Prof Dr C.G. Kleer (1/750, 1 h) ARSc (30 min)
a EGFR.
b Warm water bath.
c Antigen retrieval solution high pH (DakoCytomation, Glostrup, Denmark).
d DakoCytomation, Glostrup, Denmark.
cells; 3 = strong complete membranous staining in
more than 10% of tumour cells). Based on this score,
the HER2/neu status was determined: Score 0–1 was
considered negative, Scores 2 and 3 was considered
positive.
Differential expression of proteins
with well-known difference in expression
in IBC and non-IBC
Previous studies showed a difference in protein ex-
pression for ER, PR, p53 and HER2/neu in IBC and
non-IBC. Steroid hormone receptor status and score,
HER2/neu status and score and p53 status (determined
as described above) were compared in the TMA of
IBC and non-IBC.
Concordance between HER2/neu status
determined using different antibodies
We compared the expression of the HER2/
neu oncoprotein determined by the HercepTest
(DakoCytomation, Glostrup, Denmark) with the ex-
pression of the HER2/neu oncoprotein determined
using the TAB250 antibody, the CB11 antibody or
a combination of both antibodies. The TAB250 and
CB11 HER2/neu score and status were determined us-
ing the same scoring system as the HercepTest. For
the combination of the CB11 and TAB250 antibody,
a doublescore and according status were calculated as
described by Sapino et al. [21].
Tissue loss
To minimise tissue loss during microtome sectioning
and tissue transfer, the TMA was incubated for 30 min
at 40◦C as described in the manual of the Beecher
Instruments Tissue Arrayer (Beecher Instruments, Sil-
ver Springs, MD, USA). To evaluate the efficiency
of this incubation, unstained microtome sections were
evaluated macroscopically. The number of empty core
biopsy positions was counted on five subsequent sec-
tions. To evaluate tissue loss caused by the aggressive
pre-treatment of certain IHC staining procedures, the
number of core biopsies and number of patients that
could be evaluated (at least one core biopsy contain-
ing tumour cells left), was compared after different
IHC staining procedures. The slides were divided into
two groups, according to pre-treatment: one group
without aggressive pre-treatment and one group with
aggressive treatment (30 min in warm water bath at
98◦C).
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Figure 2. Results of control haematoxylin–eosin slide of TMA. Black rounds represent informative core biopsies (core biopsies containing
breast cancer cells), white rounds represent non-informative core biopsies (empty core biopsies or core biopsies not containing any cancer
cells). Seventeen of 34 (50%) IBC tumours and two of 41 (4.9%) non-IBC tumours had more informative than non-informative core biopsies
( p < 0.0001). In eight of 34 (23.5%) IBC tumours all core biopsies were non-informative, compared to one of 41 non-IBC tumours (2.4%)
( p < 0.01).
Differential protein expression
Differential protein expression of CA IX, EGFR,
RhoC and E-Cadherin in IBC and non-IBC was stud-
ied. For CA IX a semi-quantitative score was calcu-
lated by multiplying the % of immunoreactive cells
with the intensity on a 0–3 scale (score 0–300). The
immunoreactivity for EGFR was evaluated on a 0–3
scale using the same scoring system as the HercepTest
(DakoCytomation, Glostrup, Denmark). The immuno-
reactivity for E-Cadherin was evaluated as described
by Kleer et al. [15]. The interpretation of the staining
for the RhoC GTPase antigen was done as described
by Kleer and van Golen [16].
Statistical analysis
Statistical analysis was done with the SPSS package,
version 11.0. Statistical significance was accepted at
p < 0.05. When describing the TMA, the presence
of core biopsies was tested using a Chi-square test
(or Fisher’s exact test when necessary). For testing
differential protein expression in IBC and non-IBC,
a Chi-square test was used for status and a non-
parametric Mann–Whitney U-test was used for scores.
Concordance between two IHC staining procedures
was studied with a Kappa test, using the criteria
according to Landis [22].
For testing normal distribution of data, we used a
Shapiro Wilk test. When data were normally distrib-




Figure 2 shows the presence and cancer cell con-
tent of all core biopsies as determined on a control
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Figure 3. Differential expression of ER, PR and HER2/neu in IBC and non-IBC. (A) ER (left) and PR (right) expression is lower in IBC
compared to non-IBC. A black round is a ER/PR positive tumour, a white round is a ER/PR negative tumour. 17.9 and 8.3% of IBC tumours
are positive for ER and PR respectively compared to 80 and 41.2% of non-IBC ( p < 0.01). (B) HER2/neu score (left) and status (right) are
higher in IBC compared to non-IBC. Left: a black round is score 3, a dark grey round is score 2, a light grey round is score 1 and a white round
is score 0; Right: a black round is HER2/neu positive, a white round is negative. 42.3% of IBC tumours were HER2/neu positive, compared to
10.8% of non-IBC tumours (pscore = 0.01; pstatus = 0.006). (ER – estrogen receptor; PR – progesterone receptor; IBC – inflammatory breast
cancer; HercepTest (DakoCytomation, Glostrup, Denmark).)
haematoxylin–eosin slide. In 17 of 34 (50.0%) IBC tu-
mours there were more non-informative cores (empty
or not containing any cancer cells) than informative
cores, compared to two of 41 (4.9%) non-IBC patients
( p < 0.0001). In eight of 34 (23.5%) IBC tumours all
cores were non-informative, compared to one of 41
non-IBC tumours (2.4%) ( p < 0.01).
Validation TMA
Concordance between results of the pathology
report and the TMA results
A good to excellent concordance between the TMA
results of IHC analysis for ER, PR, HER2/neu and p53
and the results of the whole tissue section IHC analysis
for these antigens was noted (κER = 0.74; κPR = 0.90;
κHER2/neu = 0.85; κp53 = 0.50).
Differential expression of proteins
with well-known difference in expression
in IBC and non-IBC
The known differential expression of ER, PR, p53 and
HER2/neu in IBC and non-IBC was confirmed on the
TMA. Figure 3 shows the results of IHC for the ER,
PR and HER2/neu antigens. 17.9 and 8.3% of the IBC
are positive for ER and PR respectively, compared to
80.0 and 41.2% for ER and PR in non-IBC (ERscore
p < 0.0001 and PRscore p = 0.002; ERstatus p < 0.0001
and PRstatus p = 0.007). For p53, differential expres-
sion in IBC and non-IBC was also found: 30.8% of
IBC tumours was p53 positive, compared to none of
the non-IBC tumours ( p < 0.001). HER2/neu, using
Table 2. Comparison of IHC HER2/neu status determined using
HercepTest versus combination of the TAB250 and CB11 antibody.
An excellent concordance was found (κ = 0.83)





a DakoCytomation, Glostrup, Denmark.
b HER2/neu TAB250 antibody.
c HER2/neu CB11 antibody.
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Table 3. Influence of pre-treatment of staining procedures on tissue loss of the TMA.
Staining procedures are divided into two groups: one without pre-treatment and one
with aggressive pre-treatment (warm water bath). The mean number of cores present
after staining differs significantly between both groups ( p = 0.015)
Pre-treatment IHC staining Number of cores
present
None Haematoxylin–eosin 199 Mean: 190.2;




Warm water bath PR 175 Mean: 157.8;
(98◦C; 30 min) ER 182 SE: 10.14
E-Cadherin 140
p53 163
a HER2/neu IHC staining using the TAB250 antibody.
b HER2/neu IHC staining using the CB11 antibody.
c EGFR.
Table 4. Differential protein expression in IBC and non-IBC as determined on our TMA
Protein expression % positive patients
(exc E-Cadherin, CA IX and EGFR: median score)
IBC Non-IBC p-value
ER 17.9 80.0 <0.001
PR 8.3 41.2 0.007
p53 30.8 0 <0.001
HER2/neu (HercepTest) 42.3 10.8 0.006
HER2/neu (TAB250 antibody) 46.4 15.4 0.007
HER2/neu (CB11 antibody) 41.4 15.0 0.025
HER2/neu (combi TAB250–CB11 antibody) 50.0 17.5 0.005
RhoC GTPase 65.4 37.5 <0.001
E-Cadherin 3.5 1 <0.001
CA IX 0 0 N.S.
EGFR 0 0 N.S.
the HercepTest, was significantly more expressed in
IBC than in non-IBC. 42.3% of IBC tumours was
HER2/neu positive compared to 10.8% of non-IBC
tumours ( pscore = 0.01; pstatus = 0.006).
Concordance between HER2/neu status
as determined by using different antibodies
An excellent concordance was found between the
HER2/neu status determined using the HercepTest
and the HER2/neu status determined using the
CB11 antibody, TAB250 antibody and combina-
tion of both (κ coëfficient respectively 0.86, 0.78
and 0.83). Table 2 shows the 2 × 2 table for Her-
cepTest and the combination of the CB11 and TAB250
antibody.
Tissue loss
The number of empty core biopsy positions was
counted macroscopically on five subsequent unstained
slides. The average number of missing biopsies was
8.2 (range 7–9) or 2.8% (range 2.4–3.1%). After
IHC staining, the number of biopsies was compared
between two groups, one without and one with an
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aggressive pre-treatment. Table 3 shows the results.
The mean number of biopsies left after IHC staining
procedures was 190.2± 2.87 and 157.8± 10.14, for
the groups without and with aggressive pre-treatment
respectively ( p = 0.015). The number of tumours that
could be evaluated differed minimally but signific-
antly: 62.6 ± 1.29 for staining procedures with ag-
gressive pre-treatment versus 66 ± 0.55 for staining
procedures without pre-treatment ( p = 0.04).
Differential protein expression
A differential expression of RhoC GTPase and E-
Cadherin in IBC and non-IBC was found: 65.4% of
IBC patients was positive for RhoC GTPase, com-
pared to 37.5% of non-IBC patients (pscore = 0.04;
pstatus < 0.0001). The median E-Cadherin score
for IBC was 3.5, compared to one for non-IBC
( p < 0.001). For CA IX and EGFR no difference in
expression was found on the TMA. Table 4 gives an
overview of differential protein expression in IBC and
non-IBC as determined on the TMA.
Discussion
We validate the use of our TMA for studying differ-
ential protein expression in IBC using three different
approaches. This validation is necessary, because het-
erogeneous expression of certain proteins can lead to
a sampling bias and misinterpretation of IHC react-
ivity on a TMA. Breast cancer is a morphologically
and genetically heterogeneous malignancy [23–30].
IBC constitute a unique subtype of breast cancer
with a characteristic infiltrative and diffuse growth
pattern with small and separated tumour cell nests
separated by tumour-related connective tissue stroma
[1]. Furthermore patients with IBC are treated with
neo-adjuvant chemotherapy before mastectomy, there-
fore availability of tissue taken before the start of
neo-adjuvant chemotherapy is limited.
A very good to excellent concordance (0.74 < κ)
between IHC results of whole tissue section examina-
tion and the TMA results was noted for ER, PR and
HER2/neu. For p53 a good concordance (0.40< κ)
was found. Stabilisation of the p53 gene product is
a heterogeneous phenomenon. Other authors found
a better concordance when comparing TMAs and
whole tissue sections in breast cancer [31, 32]. This
is the first report of the construction of a TMA of
IBC, and the concordance between IHC results of
whole tissue sections and those of TMA has therefore
never been studied before in this particular popula-
tion. Camp et al. investigated in breast cancer how
many core biopsies per patient are needed to repro-
duce IHC results of whole tissue sections on TMA
for ER, PR and HER2/neu. They concluded that ana-
lysis of two cores is comparable to analysis of whole
tissue sections in 95% of cases [33]. Because of the
particular biology and diffuse growth pattern of IBC,
we planned to include five core biopsies per IBC pa-
tient and three core biopsies per non-IBC patient to
compensate for the sampling bias and tissue loss. Al-
though five core biopsies per IBC patient were planned
in our TMA, only half of the patients had three or
more core biopsies containing tumour cells. Eight IBC
patients did not have any core biopsy with tumour.
Because of the diffuse growth pattern, the IBC core
biopsies present contained less tumour compared to
the core biopsies of non-IBC patients. More than five
cores/patient might thus be necessary.
The most powerful validation for the use of the
TMA for studying differential protein expression in
IBC, was the confirmation of the known differences
in expression of ER, PR, p53 and HER2/neu between
IBC and non-IBC. The aim of the TMA technology
is not to reproduce results of individual tumours but
to show differences between large groups of tumours
under standardised experimental conditions. IBC is a
rare subtype of breast cancer. Our population is there-
fore substantial. Underestimation of expression due
to tissue heterogeneity will not influence differential
expression in different groups, when all groups are
subjected to underestimation to the same extent. In
our TMA this is not completely so: IBC has a diffuse
growth pattern, therefore IBC cores contain less tu-
mour tissue than non-IBC cores with often large areas
containing only tumour-related stroma or incorporated
normal breast tissue. The lower expression of ER and
PR in IBC could be due to the underestimation of
steroid hormone expression in IBC versus non-IBC.
Nevertheless, steroid hormone receptors are relatively
homogeneously expressed and differences have been
shown before [3, 5, 6, 8, 10, 11]. The possible un-
derestimation of the expression of heterogeneously ex-
pressed proteins, such as mutated p53 and HER2/neu,
in IBC makes the confirmation of the overexpres-
sion of the mutated p53 and the HER2/neu oncogen
product in IBC even more significant [7, 9]. Differen-
tial expression for ER, PR, p53 and HER2/neu and the
concordance between results for the HER2/neu status
using three different antibodies (HercepTest, TAB250
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and CB11) has to be considered as a validation of the
use of the TMA.
Another technical concern using TMA technology
is tissue loss. Tissue core biopsies can be lost during
microtome sectioning, tissue transfer and IHC stain-
ing procedures. In our study, the tissue loss during
microtome sectioning and tissue transfer was minimal
(2.80%) even without using the Adhesive Tape System
(Instrumedics Inc, Hackensack, NJ, USA). Incubation
of our TMA for 30 min at 40◦C is therefore a good
method to minimise tissue loss. Tissue core biopsies
were lost in IHC staining procedures with aggress-
ive pre-treatment: 157.8 ± 10.14 biopsies left versus
190.2 ± 2.87 if no pre-treatment was done. Taking
a higher number of core biopsies per patient might
be necessary to minimise the loss of tumours/patients
suitable for evaluation (no pre-treatment 66 ± 0.55 v.s.
aggressive pre-treatment 62.6 ± 1.29).
Our TMA will primarily be used to validate res-
ults of gene microarray studies in IBC. A number of
proteins, that are thought to play a role in IBC are
studied in this paper. van Golen et al. described a
role for RhoC GTPase in the IBC phenotype. Normal
epithelial breast cancer cells transfected with RhoC
GTPase show phenotypical aspects of IBC cell lines:
they become more motile and invasive [34]. Recently,
Kleer et al. found that expression of RhoC GTPase
is present in a high proportion of primary IBC tu-
mours and that it predicts the metastatic potential of
invasive breast carcinomas smaller than 1 cm [16]. In
the present study, we confirm the higher expression
of RhoC GTPase in IBC. RhoC GTPase is also con-
sidered to play a role in the intense angiogenesis in
IBC [35]. Our group previously showed that the in-
creased angiogenesis in IBC is only partially hypoxia
driven. On our TMA we do not find a difference in
the expression of the hypoxia marker CA IX between
IBC and non-IBC. Hypoxia can be a very local phe-
nomenon, leading to very heterogeneous expression of
CA IX. We confirm a higher expression of E-Cadherin
in IBC. IBC seems to be an exception on the loss of E-
Cadherin expression with dedifferentiation [36]. Kleer
et al. and Colpaert et al. found that IBC tumours ex-
press high levels of E-Cadherin protein [15, 17]. The
cause of this overexpression is still uncertain. EGFR
might be involved since stimulation of the EGFR by
EGF and TGF-α results in a diminished expression of
E-Cadherin [37]. Expression of the EGFR is associ-
ated with an invasive phenotype and worse prognosis
[36]. Nevertheless, Guerin et al. showed that EGFR
was less expressed in IBC [9]. We cannot confirm
these findings on our TMA, this might suggest that
these pathways are equally utilised in both types of
breast cancer.
In conclusion we validated the TMA technology
to study differential protein expression in IBC. Equal
expression described by TMA technology for IBC
and non-IBC can be caused by an equal pheno-
type for that protein or by a sampling-bias because
of tissue heterogeneity. Our TMA will therefore be
used for a first impression of the protein expression
differences between IBC and non-IBC. It will be used
in translational IBC research in our laboratory for con-
firmation of results of further experiments in general,
and molecular biological experiments in particular, in-
vestigating the mechanisms causing the unique IBC
phenotype.
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